找化学品上960化工网!
960化工网

阿米卡星 | 37517-28-5

阿米卡星
Amikacin
37517-28-5
C22H43N5O13
585.6025
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:阿米卡星结构式
37768
阿米卡星价格
简介
阿米卡星是氨基糖苷类抗生素,为白色或类白色粉末或结晶性粉末;几乎无臭,无味。其作用机制是作用于细菌体内的核糖体,抑制细菌蛋白质合成,并破坏细菌细胞壁的完整性,致使细菌细胞膜破坏,细胞死亡。适用于革兰阴性杆菌和对青霉素耐药的金黄色葡萄球菌引起的感染。肌肉注射或静脉滴注给药,静脉滴注的半衰期约为2h,无尿时可长达30h,很少与蛋白结合。主要引起耳蜗神经损害,耳、肾毒性与庆大霉素相仿。阿米卡星依靠于细菌30S亚基结合,阻断细菌蛋白质合成而起到抗菌作用

名称和标识符
MDL MFCD00883675
InChIKey LKCWBDHBTVXHDL-RMDFUYIESA-N
Inchi 1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
SMILES O([C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])N([H])[H])O[H])[C@]1([H])[C@]([H])([C@@]([H])([C@]([H])(C([H])([H])[C@@]1([H])N([H])C([C@]([H])(C([H])([H])C([H])([H])N([H])[H])O[H])=O)N([H])[H])O[C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])O[H])O[H]
别名信息
- 中文别名 -
  • 阿米卡星
  • 阿米卡霉素
  • 丁胺卡那霉素
  • 阿米卡星(丁胺卡那霉素)二水合物
  • 氨基羟丁基卡那霉素A
  • 抗菌素BBK8
  • 丁胺卡那霉素碱
  • 4,4-(二甲基环己烯-1-基)硼酸频那醇酯
  • 阿米卡星 EP标准品
  • 阿米卡星 USP标准品
  • 阿米卡星(丁安卡那)
  • 阿米卡星标准品
  • 阿米卡星碱
  • 丁胺卡那霉素(阿米卡星)水合物 标准品
- 英文别名 -
  • Amikacin
  • AMIKACIN DIHYDRATE
  • 1-N-[L(-)-4-AMINO-2-HYDROXY-BUTYRYL]KANAMYCIN A
  • N1-[(S)-4-AMINO-2-HYDROXYBUTYRYL]-KANAMYCIN A
  • N1-[(S)-4-AMINO-2-HYDROXYBUTYRYL]KANAMYCIN A DIHYDRATE
  • (s)-y
  • 1-n-(l(-)-gamma-amino-alpha-hydroxybutyryl)kanamycina
  • amicacin
  • amikin
  • amiklin
  • AMK
  • bb-k8
  • biklin
  • D-Streptamine
  • kaminax
  • lukadin
  • mikavir
  • novamin
  • amikacine
  • Amikacinum
  • Amikacina
  • Amikavet
  • Amiglyde-V
  • Amikacillin
  • Arikace
  • Antibiotic BB-K 8
  • AMIKACIN SULFATE
  • Amukin
  • Amikacinum [INN-Latin]
  • Amikacine [INN-French]
  • Amikacina [INN-Spanish]
  • Amikacin Base
  • BB-K 8
  • Briclin
  • Pierami
  • ANTIBIOTIC BB-K8
  • 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
  • Amikacin hydrate
  • C22H43N5O13
  • LKCWBDHBTVXHDL-RM
  • (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D
  • BPBio1_000671
  • Lukadin
  • D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
  • Tox21_111201_1
  • 37517-28-5
  • Kaminax
  • Amikacinum (Latin)
  • Q408529
  • D02543
  • Amikacin Dihydrate
  • BAY41-6551
  • DTXSID3022586
  • Amikacinum (INN-Latin)
  • nktr-061
  • DTXCID002586
  • UNII-84319SGC3C
  • AB00513828_06
  • NS00006181
  • J01GB06
  • SR-01000722004-6
  • A823716
  • Amikin
  • NSC 177001
  • SR-01000722004
  • Potentox
  • AMIKACIN [USP MONOGRAPH]
  • AKN
  • Amikacin, Antibiotic for Culture Media Use Only
  • Amikacin (USP/INN)
  • AMIKACIN [MI]
  • MFCD00883675
  • amikacin
  • EINECS 253-538-5
  • D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-N1-((2S)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-
  • (S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide
  • AMIKACIN [MART.]
  • Amikacin
  • 6-O-(3-Amino-3-deoxy-?-d-glucopyranosyl)-4-O-(6-amino-6-deoxy-?-d-glucopyranosyl)-1-N-[(2S)-4-amino-2-hydroxybutanoyl]-2-deoxy-d-streptamine
  • AKOS005383276
  • AMIKACIN [WHO-DD]
  • Amikacine (INN-French)
  • (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide
  • AMIKACIN (USP-RS)
  • EN300-7481440
  • Amikozit
  • C06820
  • D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-
  • 37517-28-5 (free base)
  • TD1 - Therapeutic Drug mixture
  • BSPBio_000609
  • O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine
  • ,6R)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide
  • Amicacin
  • AMIKACIN [WHO-IP]
  • N1-[(S)-4-Amino-2-hydroxybutyryl]kanamycin A
  • AB00513828
  • Amikacina (INN-Spanish)
  • GTPL10894
  • AMIKACIN [VANDF]
  • NCGC00093350-05
  • Amikacin (USP:INN:BAN)
  • BDBM50237603
  • HY-B0509A
  • CHEMBL177
  • SCHEMBL2985
  • CHEBI:2637
  • Tox21_111201
  • W-106531
  • O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE
  • D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
  • AMIKACIN (EP MONOGRAPH)
  • CAS-37517-28-5
  • O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine
  • (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
  • S01AA21
  • Arikayce liposomal
  • (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butanamide
  • Mikavir
  • Amikacin,(S)
  • Amikacin free base
  • DB00479
  • O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine
  • Amikin (Disulfate)
  • D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-
  • D06AX12
  • (S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4-((2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yloxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide
  • NCGC00093350-02
  • AMIKACIN [EP MONOGRAPH]
  • NCGC00093350-03
  • O-3-AMINO-3-DEOXY-alpha-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-alpha-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE
  • 84319SGC3C
  • AMIKACINUM [WHO-IP LATIN]
  • HSDB 3583
  • NSC-177001
  • BAY 41-6551
  • D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-
  • AMIKACIN [HSDB]
  • Prestwick3_000395
  • MAT2501
  • BB-K8
  • AMIKACIN [JAN]
  • (2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S
  • AS-76985
  • AMIKACIN [INN]
  • (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide
  • AMIKACIN [USP-RS]
  • NSC177001
  • Amikacin (free base)
  • (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide
  • AMIKACIN (USP MONOGRAPH)
  • (2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S ,6R)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide
  • AT03 - Amikacin
  • Amikacin [USP:INN:BAN]
  • AMIKACIN (MART.)
  • MFCD11045969
物化性质
实验特性
LogP -5.23210
PSA 331.94000
Merck 13,404
折射率 1.7500 (estimate)
水溶性 Soluble in water (partly).
沸点 642.23°C (rough estimate)
熔点 203℃
闪点 547.6 °C
溶解度 H2O: 50 mg/mL, clear, colorless
颜色与性状 未确定
溶解性 未确定
比旋光度 D23 +99° (c = 1.0 in water)
密度 1.3764 (rough estimate)
计算特性
精确分子量 585.28600
氢键供体数量 13
氢键受体数量 17
可旋转化学键数量 10
同位素质量 585.286
重原子数量 40
复杂度 819
同位素原子数量 0
确定原子立构中心数量 16
不确定原子立构中心数量 0
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP) -7.9
表面电荷 0
拓扑分子极性表面积 332
国际标准相关数据
EINECS 3583
相关文献
专业数据库参考
PubChemId 37768
化合物详情(旧版)

阿米卡星物理化学性质

白色结晶性粉末,几乎无臭,无味。极易溶于水,不溶于甲醇、丙醇、乙醚等有机溶剂。氨基苷类抗生素。

阿米卡星产品用途

用于对卡那霉素、庆大霉素耐药菌株引起的尿路、肺部等感染及绿脓、变形等杆菌引起的败血症。

阿米卡星用法和用量

1.成人肌内注射或静脉滴注,尿路感染,每12小时0.25g;用于其他全身感染,按体重每8小时5mg/kg,或每12小时7.5mg/kg。成人每天不超过1.5g,疗程不超过10天。
2.新生儿肌内注射或静脉滴注首剂按体重10mg/kg,继以每12小时7.5mg/kg;儿童用量与成人同。3.肌注或静滴,一日15mg/kg,分2-3次给药,成人日量不超过1.5g.单纯尿路感染一次250mg,一日2次即可.新生儿首次10mg/kg,以后每12小时用7.5mg/kg.一般一疗程不超过10天.

阿米卡星化学品安全说明书(MSDS)

类别    有毒物品
毒性分级  中毒
急性毒性    口服-小鼠 LD50:>6000 毫克/公斤; 腹腔-小鼠 LD50: 750 毫克/公斤
可燃性危险特性    可燃; 燃烧产生有毒氮氧化物烟雾
储运特性    库房通风低温干燥
灭火剂     干粉,泡沫,沙土,二氧化碳, 雾状水

产品用途
用于对卡那霉素、庆大霉素耐药菌株引起的尿路、肺部等感染及绿脓、变形等杆菌引起的败血症。
阿米卡星推荐生产厂家
960化工网为您提供阿米卡星专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:37517-28-5,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等;| WAP 版:37517-28-5
平台客服 平台客服

平台在线客服